Clinical Trial Update: A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and effectiveness of ADX-N05 for excessive daytime sleepiness in narcolepsy completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy

Drugs mentioned

• ADX-N05

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Narcolepsy | Phase 2 | Status: COMPLETED | Results posted: 2021-07-06